<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classification criteria for systemic lupus erythematosus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classification criteria for systemic lupus erythematosus</h1>
<div class="graphic"><div class="figure"><div class="ttl">Classification criteria for systemic lupus erythematosus</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup> <colgroup width="40%"></colgroup> <colgroup width="10%"></colgroup> <colgroup width="40%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1" colspan="2">ACR criteria<sup>[1,2]</sup></td> <td class="subtitle1" colspan="2">SLICC criteria<sup>[3]</sup></td> </tr> <tr class="divider_bottom"> <td class="centered" colspan="2">(4 of 11 criteria)*</td> <td class="centered" colspan="2">(4 of 17 criteria, including at least 1 clinical criterion and 1 immunologic criterion;<sup>¶</sup> <strong>OR</strong> biopsy-proven lupus nephritis<sup>Δ</sup>)</td> </tr> <tr class="border_bottom_thick"> <td class="subtitle2">Criterion</td> <td class="subtitle2">Definition</td> <td class="subtitle2">Criterion</td> <td class="subtitle2">Definition</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left_white" colspan="2"> </td> <td class="subtitle2_left_white" colspan="2">Clinical criteria</td> </tr> <tr class="divider_bottom"> <td>Malar rash</td> <td>Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds</td> <td class="indent1" rowspan="2">Acute cutaneous lupus</td> <td rowspan="2">Lupus malar rash (do not count if malar discoid); bullous lupus; toxic epidermal necrolysis variant of SLE; maculopapular lupus rash; photosensitive lupus rash (in the absence of dermatomyositis); <strong>OR</strong> subacute cutaneous lupus (nonindurated psoriasiform and/or annular polycyclic lesions that resolve without scarring, although occasionally with postinflammatory dyspigmentation or telangiectasias)</td> </tr> <tr class="divider_bottom"> <td>Photosensitivity</td> <td>Skin rash as a result of unusual reaction to sunlight, by patient history or clinician observation</td> </tr> <tr class="divider_bottom"> <td>Discoid rash</td> <td>Erythematosus raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur in older lesions</td> <td class="indent1">Chronic cutaneous lupus</td> <td>Classic discoid rash; localized (above the neck); generalized (above and below the neck); hypertrophic (verrucous) lupus; lupus panniculitis (profundus); mucosal lupus; lupus erythematosus tumidus; chilblains lupus; <strong>OR</strong> discoid lupus/lichen planus overlap</td> </tr> <tr class="divider_bottom"> <td> </td> <td> </td> <td class="indent1">Nonscarring alopecia</td> <td>Diffuse thinning or hair fragility with visible broken hairs (in the absence of other causes, such as alopecia areata, drugs, iron deficiency, and androgenic alopecia)</td> </tr> <tr class="divider_bottom"> <td>Oral ulcers</td> <td>Oral or nasopharyngeal ulceration, usually painless, observed by a clinician</td> <td class="indent1">Oral or nasal ulcers</td> <td>Palate, buccal, tongue, <strong>OR</strong> nasal ulcers (in the absence of other causes, such as vasculitis, Behçet syndrome, infection [herpesvirus], inflammatory bowel disease, reactive arthritis, and acidic foods)</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Arthritis</td> <td class="divider_bottom" rowspan="2">Nonerosive arthritis involving 2 or more peripheral joints, characterized by tenderness, swelling, or effusion</td> <td class="indent1 divider_bottom" rowspan="2">Joint disease</td> <td>Synovitis involving 2 or more joints, characterized by swelling or effusion <strong>OR</strong></td> </tr> <tr class="divider_bottom"> <td>Tenderness in 2 or more joints and at least 30 minutes of morning stiffness</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Serositis</td> <td>Pleuritis – Convincing history of pleuritic pain or rubbing heard by a clinician or evidence of pleural effusion <strong>OR</strong></td> <td class="indent1 divider_bottom" rowspan="2">Serositis</td> <td>Typical pleurisy for more than 1 day, pleural effusions, or pleural rub, <strong>OR</strong></td> </tr> <tr class="divider_bottom"> <td>Pericarditis – Documented by ECG, rub, or evidence of pericardial effusion</td> <td>Typical pericardial pain (pain with recumbency improved by sitting forward) for more than 1 day, pericardial effusion, pericardial rub, or pericarditis by electrocardiography in the absence of other causes, such as infection, uremia, and Dressler syndrome</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Renal disorder</td> <td>Persistent proteinuria greater than 500 mg/24 hours or greater than 3+ if quantitation not performed <strong>OR</strong></td> <td class="indent1 divider_bottom" rowspan="2">Renal</td> <td>Urine protein-to-creatinine ratio (or 24-hour urine protein) representing 500 mg protein/24 hours, <strong>OR</strong></td> </tr> <tr class="divider_bottom"> <td>Cellular casts – May be red cell, hemoglobin, granular, tubular, or mixed</td> <td>Red blood cell casts</td> </tr> <tr class="divider_bottom"> <td>Neurologic disorder</td> <td>Seizures <strong>OR</strong> psychosis – In the absence of offending drugs or known metabolic derangements (uremia, ketoacidosis, or electrolyte imbalance)</td> <td class="indent1">Neurologic</td> <td>Seizures; psychosis; mononeuritis multiplex (in the absence of other known causes, such as primary vasculitis); myelitis; peripheral or cranial neuropathy (in the absence of other known causes, such as primary vasculitis, infection, and diabetes mellitus); <strong>OR</strong> acute confusional state (in the absence of other causes, including toxic/metabolic, uremia, drugs)</td> </tr> <tr> <td class="border_bottom_thick" rowspan="4">Hematologic disorder</td> <td class="border_bottom_thick" rowspan="4"> <p>Hemolytic anemia – With reticulocytosis <strong>OR</strong></p> <p>Leukopenia – Less than 4000/mm<sup>3</sup> total on 2 or more occasions <strong>OR</strong></p> <p>Lymphopenia – Less than 1500/mm<sup>3</sup> on 2 or more occasions <strong>OR</strong></p> Thrombocytopenia – Less than 100,000/mm<sup>3</sup> (in the absence of offending drugs)</td> <td class="indent1">Hemolytic anemia</td> <td>Hemolytic anemia</td> </tr> <tr> <td class="indent1" rowspan="2">Leukopenia or lymphopenia</td> <td>Leukopenia (&lt;4000/mm<sup>3</sup> at least once) (in the absence of other known causes, such as Felty syndrome, drugs, and portal hypertension), <strong>OR</strong></td> </tr> <tr> <td>Lymphopenia (&lt;1000/mm<sup>3</sup> at least once) (in the absence of other known causes, such as glucocorticoids, drugs, and infection)</td> </tr> <tr class="border_bottom_thick"> <td class="indent1">Thrombocytopenia</td> <td>Thrombocytopenia (&lt;100,000/mm<sup>3</sup>) at least once in the absence of other known causes, such as drugs, portal hypertension, and thrombotic thrombocytopenic purpura</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left_white" colspan="2"> </td> <td class="subtitle2_left_white" colspan="2">Immunologic criteria</td> </tr> <tr class="divider_bottom"> <td>ANA</td> <td>An abnormal titer of ANA by immunofluorescence or an equivalent assay at any point in time and in the absence of drugs known to be associated with "drug-induced lupus" syndrome</td> <td class="indent1">ANA</td> <td>ANA level above laboratory reference range</td> </tr> <tr> <td class="divider_bottom" rowspan="3">Immunologic disorders</td> <td class="divider_bottom" rowspan="3"> <p>Anti-DNA – Antibody to native DNA in abnormal titer <strong>OR</strong></p> <p>Anti-Sm – Presence of antibody to Sm nuclear antigen <strong>OR</strong></p> Positive antiphospholipid antibody on: <ol> <li>An abnormal serum level of IgG or IgM anticardiolipin antibodies <strong>OR</strong></li> <li>A positive test result for lupus anticoagulant using a standard method <strong>OR</strong></li> <li>A false-positive serologic test for syphilis known to be positive for at least 6 months and confirmed by <em>Treponema pallidum</em> immobilization or fluorescent treponemal antibody absorption test</li> </ol> </td> <td class="indent1">Anti-dsDNA</td> <td>Anti-dsDNA antibody level above laboratory reference range (or &gt;2-fold the reference range if tested by ELISA)</td> </tr> <tr> <td class="indent1">Anti-Sm</td> <td>Presence of antibody to Sm nuclear antigen</td> </tr> <tr class="divider_bottom"> <td class="indent1">Antiphospholipid</td> <td>Antiphospholipid antibody positivity as determined by any of the following: Positive test result for lupus anticoagulant; false-positive test result for rapid plasma reagin; medium- or high-titer anticardiolipin antibody level (IgA, IgG, or IgM); or positive test result for anti-beta 2-glycoprotein I (IgA, IgG, or IgM)</td> </tr> <tr class="divider_bottom"> <td> </td> <td> </td> <td class="indent1">Low complement</td> <td>Low C3; low C4; <strong>OR</strong> low CH50</td> </tr> <tr> <td> </td> <td> </td> <td class="indent1">Direct Coombs test</td> <td>Direct Coombs test in the absence of hemolytic anemia</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>ACR: American College of Rheumatology; SLICC: Systemic Lupus International Collaborating Clinics; SLE: systemic lupus erythematosus; ECG: electrocardiogram; ANA: antinuclear antibodies; Anti-Sm: anti-Smith antibody; IgG: immunoglobulin G; IgM: immunoglobulin M; Anti-dsDNA: anti-double-stranded DNA; ELISA: enzyme-linked immunosorbent assay; IgA: immunoglobulin A.</p>
<p>* For the ACR criteria, no distinction is made between clinical and immunologic criteria in determining whether the required number has been met. The classification is based upon 11 criteria. For the purpose of identifying patients in clinical studies, a person is said to have SLE if any 4 or more of the 11 criteria are present, serially or simultaneously, during any interval of observation.</p>
<p>¶ For the SLICC criteria, criteria are cumulative and need not be presently concurrently. A patient is classified as having SLE if he or she satisfies 4 of the clinical and immunologic criteria used in the SLICC classification criteria, including at least 1 clinical criterion and 1 immunologic criterion.</p>
Δ Alternatively, according to the SLICC criteria, a patient is classified as having SLE if he or she has biopsy-proven nephritis compatible with SLE in the presence of ANAs or anti-dsDNA antibodies.</div><div class="graphic_reference">References:
<ol>
<li>Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271.</li>
<li>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). Arthritis Rheum 1997; 40:1725.</li>
<li>Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677.</li>
</ol></div><div id="graphicVersion">Graphic 86633 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
